Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been assigned a consensus recommendation of “Moderate Buy” from the four analysts that are presently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $85.25.

A number of research firms have recently issued reports on PBH. DA Davidson reissued a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Sidoti cut Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a research report on Monday, December 9th. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Finally, Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $75.35 on Tuesday. Prestige Consumer Healthcare has a 1 year low of $60.00 and a 1 year high of $86.36. The stock has a market capitalization of $3.72 billion, a PE ratio of 18.33, a PEG ratio of 2.15 and a beta of 0.50. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. The stock has a 50-day simple moving average of $79.63 and a 200-day simple moving average of $75.19.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. Prestige Consumer Healthcare’s revenue for the quarter was down .9% on a year-over-year basis. During the same period in the previous year, the business earned $1.07 EPS. On average, analysts predict that Prestige Consumer Healthcare will post 4.46 earnings per share for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In related news, insider William P’pool sold 8,987 shares of the stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares in the company, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the sale, the chief executive officer now owns 320,952 shares in the company, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,810 shares of company stock valued at $3,187,300 in the last three months. Corporate insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Kestra Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare in the 4th quarter valued at $27,000. Northwestern Mutual Wealth Management Co. boosted its holdings in Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares during the last quarter. nVerses Capital LLC increased its position in Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares during the period. Huntington National Bank raised its holdings in Prestige Consumer Healthcare by 39.9% during the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after purchasing an additional 181 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its position in Prestige Consumer Healthcare by 7,112.5% during the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after purchasing an additional 1,138 shares during the period. 99.95% of the stock is owned by institutional investors and hedge funds.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.